Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $3.3 million.

  • Marker Therapeutics' Total Liabilities fell 331.82% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 331.82%. This contributed to the annual value of $3.5 million for FY2024, which is 1267.07% up from last year.
  • According to the latest figures from Q3 2025, Marker Therapeutics' Total Liabilities is $3.3 million, which was down 331.82% from $4.3 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Total Liabilities peaked at $24.3 million during Q2 2022, and registered a low of $2.0 million during Q2 2024.
  • Its 5-year average for Total Liabilities is $10.3 million, with a median of $4.3 million in 2025.
  • As far as peak fluctuations go, Marker Therapeutics' Total Liabilities surged by 36799.09% in 2021, and later crashed by 8797.66% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Total Liabilities stood at $24.1 million in 2021, then tumbled by 38.63% to $14.8 million in 2022, then crashed by 79.25% to $3.1 million in 2023, then increased by 12.67% to $3.5 million in 2024, then fell by 3.42% to $3.3 million in 2025.
  • Its Total Liabilities was $3.3 million in Q3 2025, compared to $4.3 million in Q2 2025 and $2.5 million in Q1 2025.